AZN
NEUTRALAstraZeneca Announces Director Appointment
The healthcare company has announced the appointment of a new non-executive director to its board.
AstraZeneca
12,470.00GBX
-0.61%
Market Cap
193.53B
Volume
1.08M
50% of avg
P/E Ratio
1727.15
EPS (TTM)
7.22
Beta
0.17
Day Range
12,424.00p - 12,586.00p
52 Week Range
9,573.50p12,470.00p12,972.00p
12,470.00p
Upcoming Events
AZN
NEUTRALAstraZeneca's Koselugo approved in EU for rare genetic condition
The biopharmaceutical company has received EU approval for its Koselugo treatment for a rare genetic condition affecting the nerves.
AZN
NEUTRALAstraZeneca Receives EU Approval for Tezspire to Treat Chronic Rhinosinusitis with Nasal Polyps
The biopharmaceutical company has received European Commission approval for its Tezspire treatment for chronic rhinosinusitis with nasal polyps.
AZN
NEUTRALAstraZeneca's Tezspire Approved by FDA for Chronic Rhinosinusitis with Nasal Polyps
The biopharmaceutical company has received FDA approval for its Tezspire treatment for a chronic respiratory condition.
AZN
NEUTRALAstraZeneca's Saphnelo Subcutaneous Formulation Recommended for EU Approval
The biopharmaceutical company received a positive CHMP opinion for a subcutaneous version of its lupus drug Saphnelo, which could provide patients with a more convenient administration option.
AZN
GOODAstraZeneca Strikes Historic Deal with US Govt to Lower Medicine Prices
The biopharmaceutical company has reached a historic agreement with the US government to lower the cost of medicines for American patients, while preserving the country's role as a global leader in innovation.
AZN
NEUTRALAstraZeneca's Baxdrostat meets primary endpoint in Phase III trial for resistant hypertension
The biopharmaceutical company reports that its drug baxdrostat demonstrated a statistically significant and clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure compared to placebo in a Phase III trial for resistant hypertension.
AZN
NEUTRALAstraZeneca reports positive results from TROPION-Breast02 trial of Datroway in triple-negative breast cancer
The biopharmaceutical company announced positive results from a Phase III trial of its Datroway treatment for triple-negative breast cancer, demonstrating statistically significant improvements in overall survival and progression-free survival.
AZN
NEUTRALAstraZeneca's Enhertu Demonstrates Improved Outcomes in Early Breast Cancer Trial
The biopharmaceutical company announced positive results from a Phase III trial of its HER2-directed antibody drug conjugate Enhertu in patients with high-risk early breast cancer.
AZN
NEUTRALAstraZeneca to harmonise its listing structure across major exchanges
The biopharmaceutical company is planning to harmonise its share listing structure to deliver a global listing for global investors.